The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer

@inproceedings{Sequeira2014TheEO,
  title={The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer},
  author={Gonzalo R Sequeira and Silvia In{\'e}s Vanzulli and Paola A Rojas and Caroline E Lamb and Lucas Luis Colombo and Maria Murgasova May and Alfredo A Molinolo and Claudia Lanari},
  booktitle={Oncotarget},
  year={2014}
}
There is clinical and experimental evidence suggesting that antiprogestins might be used for the treatment of selected breast cancer patients. Our aim was to evaluate the effect of albumin-bound paclitaxel (Nab-paclitaxel) and pegylated doxorubicin liposomes (PEG-LD) in combination with mifepristone (MFP) in experimental breast cancer models expressing different ratios of progesterone receptor (PR) isoforms A and B. We used two antiprogestin-responsive (PRA>PRB) and two resistant (PRA<PRB… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Progesterone receptor isoforms in normal and malignant breast.

Ernst Schering Foundation symposium proceedings • 2007
View 13 Excerpts
Highly Influenced

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…